Highlights of 2024: The year the obesity market took shape The market for anti-obesity medications (AOMs) reached a major milestone in 2024 with global spend exceeding $30Bn for the first time, an over ten-fold increase since 2020
Kaji I, Karaki S, Tanaka R, Kuwahara A
Learn more in our company announcement here: novonordisk.com/content/nncorp #PRESS The first GLP-1 pill for the treatment of obesity is now approved by the US Food and Drug Administration (FDA)
Inko/Myline Nutriche Diet + Pharma GmbH, Am Espan 1-3, 91154, Roth, DE
The Phosphodiesterase (PDE) 4 inhibitor roflumilast, which is clinically approved for chronic obstructive pulmonary disease (COPD), has been reported to reverse BLM-induced elevations in glycine and proline and moderately restore levels of glutamate, alanine, and arginine
J., Licklider, J